Jazz’s development pipeline includes the clinical development of new therapies to treat unmet medical needs, line extensions for existing products, and the generation of additional clinical data for existing products.
1 U.S. approved indication.
2 NDA submission assumes positive study outcome.
3 Evaluation of deuterated oxybate continues as part of the once-nightly development process.
4 Evaluating early stage product candidates, including recombinant pegaspargase.
t-AML = Therapy-Related Acute Myeloid Leukemia, AML-MRC = AML with Myelodysplasia-Related Changes, FDA = U.S. Food and Drug Administration, MAA = Marketing Authorization Application, ES = Excessive Sleepiness, OSA = Obstructive Sleep Apnea, NDA = New Drug Application, sNDA = Supplemental New Drug Application, VOD = Hepatic Veno-occlusive Disease, FPI = First Patient In, EDS = Excessive Daytime Sleepiness, GvHD = Graft versus Host Disease, ALL = Acute Lymphoblastic Leukemia